View:
Download DOC
Download PDF
Download XLS
Form 8-K Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 18, 2010  

Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)


Michigan 		 
0-22025 		 
943096597
(State or other jurisdiction
of incorporation) 		  (Commission File Number)   (IRS Employer Identification No.)


 
24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, Michigan 		 
48106 		 
  (Address of principal executive offices)   (Zip Code)  

Registrant's telephone number, including area code:   (734) 930-5555



________________________________________________________________________________
(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    [    ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [    ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [    ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [    ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On February 18, 2010 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

    Exhibit 99.1.       Press release dated February 18, 2010

SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Aastrom Biosciences, Inc.
(Registrant)
February 18, 2010
(Date) 		  /s/   TIMOTHY M. MAYLEBEN
Timothy M. Mayleben
Chief Executive Officer and President

  Exhibit Index
  99.1 Press release dated February 18, 2010






Aastrom One-for-Eight Reverse Stock Split Now Effective

EXHIBIT 99.1

Aastrom One-for-Eight Reverse Stock Split Now Effective

ANN ARBOR, Mich., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its previously announced one-for-eight reverse stock split of the company's issued and outstanding common shares is now effective. This reverse split is intended to increase the per share trading price of Aastrom's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on NASDAQ and to attract greater institutional ownership of the company's shares. As a result of the reverse stock split, every eight shares of the company's common stock that were issued and outstanding immediately prior to the opening of trading today will automatically be combined into one issued and outstanding share without any change in the par value of such shares and the number of authoriz ed but unissued shares of the company's common stock will be proportionally reduced.

Concurrent with the effectiveness of the reverse stock split, the ticker symbol will change from ASTM to ASTMD. The ticker symbol will revert to ASTM on Thursday, March 18, 2010.

About Aastrom Biosciences

Aastrom Biosciences is developing autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies using a patient's own bone marrow that can be delivered directly to damaged tissues. Aastrom has advanced this technology into late-stage clinical development and is conducting two Phase 2 clinical trials to treat dilated cardiomyopathy and a Phase 2b clinical trial to treat critical limb ischemia. For more information, please visit Aastrom's website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663

This document contains forward-looking statements which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

CONTACT:  Berry & Company
          Media:
          Stephen Zoegall
          (212) 253-8881
          szoegall@berrypr.com

          Aastrom Biosciences
          Investors:
          Kimberli O'Meara
          (734) 930-5777
          ir@aastrom.com